© 2005-2012 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.
Overall, GTTs are rare. In the United States, GTTs account for less than 1% of all cancers that start in a woman's reproductive system (a grouping called gynecologic cancers). A hydatidiform mole may develop in one in 1,000 pregnancies and 15% of these cases become malignant (cancerous).
Choriocarcinoma is very rare, occurring in about two to seven pregnancies out of 100,000 in the United States. Molar pregnancies occur much more often in Asian and African countries than in the United States.
GTTs are typically curable, especially if found early.
Cancer statistics should be interpreted with caution. These estimates are based on data from thousands of women with this type of cancer in the United States, but the actual risk for a particular individual may differ. It is not possible to tell a woman how long she will live with a GTT. Learn more about understanding statistics.
Statistics source: American Cancer Society.